Transnational cancer research lab | Felsenstein Medical Research Center
Transnational cancer research lab | Felsenstein Medical Research Center
Frontiers | Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System | Pharmacology
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) - Annals of Oncology
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
Team - ADM Capital
Our Team – CTG-Pharma
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson | Business Wire
The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
Study: COVID-19 shots shown effective in cancer patients up to 4 months later - UPI.com
First-of-its-kind study in Israel finds that cancer patients are safe for COVID-19 vaccines - EJP
Our Team – CTG-Pharma
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
Transnational cancer research lab | Felsenstein Medical Research Center
First-of-its-kind study in Israel finds that cancer patients are safe for COVID-19 vaccines - EJP
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients | Business Wire
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | NEJM
COVID vaccine effective for 90% of cancer patients, Israeli study finds | The Times of Israel
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry | npj Breast Cancer
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
